Table 3 Summary of plan complexity indices and delivery accuracy for the 2-group plans.

From: Novel DCAT plans in stereotactic body radiotherapy for stage I/II centrally located non-small-cell lung cancer

Item

Planning Goal

DCAT

VMAT

P Value

Segments

N/A

104.00 (73.50–127.00)

129.00 (111.50–135.50.50.50)

0.001*

MUs

N/A

1738.00 (1650.95–2114.00)

2265.00 (2129.50–2846.80.50.80)

< 0.001*

BOT (s)

N/A

161.00 (150.60–178.50.60.50)

169.80 (159.25–213.50)

0.007*

γ passing rates (%)

2%/2mm > 95

99.20 (98.80–99.75.80.75)

98.80 (97.80–99.70)

0.236

2%/1mm > 85

93.70 (92.45–94.60)

91.90 (88.55–94.00.55.00)

0.016*

1%/2mm > 90

97.20 (95.65–98.25)

96.60 (94.90–98.75.90.75)

0.757

  1. Median (IQR) was reported. MUs, monitor units; BOT, beam-on time. A statistically significant difference to the VMAT result is indicated by an asterisk (*). Abbreviations: N/A not applicable, DCAT dynamic conformal arc therapy, VMAT volumetric-modulated arc therapy, MUs monitor units, BOT beam-on time.
Back to article page